Veru’s drug lessens loss of lean mass in patients taking Wegovynews2025-01-27T15:56:21+00:00January 27th, 2025|Endpoints News|
Updated: Akero redeems its failure in severe MASH with longer-term datanews2025-01-27T12:04:17+00:00January 27th, 2025|Endpoints News|
Agenus continues partnership talks for anti-CTLA-4 combo with new Phase 2 datanews2025-01-25T17:15:26+00:00January 25th, 2025|Endpoints News|
Merck and Eisai reveal late-stage fail for Keytruda and Lenvima in gastroesophageal cancernews2025-01-24T20:00:55+00:00January 24th, 2025|Endpoints News|
The crucial obesity data to watch for this yearnews2025-01-24T16:27:45+00:00January 24th, 2025|Endpoints News|
AstraZeneca allocates $570M for Canadian expansion, looks to add 700 new jobsnews2025-01-24T13:39:49+00:00January 24th, 2025|Endpoints News|
Novo Nordisk’s amycretin prompts 22% weight loss in early obesity trialnews2025-01-24T12:00:40+00:00January 24th, 2025|Endpoints News|
ALX Oncology to make case for accelerated approval with evorpacept in gastric cancernews2025-01-24T11:30:49+00:00January 24th, 2025|Endpoints News|
Anthos’ detailed mid-stage data back its anticoagulant, but can the drug succeed where Bayer’s failed?news2025-01-23T11:46:45+00:00January 23rd, 2025|Endpoints News|
Chinese startup begins first clinical trial using CRISPR to edit cells directly in the bone marrownews2025-01-22T20:02:34+00:00January 22nd, 2025|Endpoints News|
